Will Gilead price its coronavirus drug for public good or company profit?

(Reuters) – Gilead Sciences Inc (GILD.O) faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus.
The drugmaker earned notoriety less than a decade ago, when it int…
Read More

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: